Lexaria Bioscience to begin new human clinical study in GLP-1

Lexaria Bioscience (LEXX) announced the engagement of the contract research organization to execute and report on its Human Pilot Study #7 that will evaluate 2 oral DehydraTECH-semaglutide compositions against commercially available Wegovy tablets. Contracts with the CRO have been signed and submissions are currently being prepared to obtain the required ethics approval from an independent review board. Study design is virtually complete and is expected to be a 5-week parallel group design, investigating 3 separate arms to assess safety & tolerability and pharmacokinetic properties that will compare salcaprozate sodium-inclusive DHT-sema tablet and capsule formulations to commercially available Wegovy tablets, under fasted pre-dose conditions. Lexaria hopes to preserve the superior safety & tolerability profiles as evidenced in previous Lexaria GLP-1 studies such as GLP-1-H25-4, combined with PK performance that matches or exceeds that of the commercial oral tablet brands Ryblesus and Wegovy. If successful, the Study results will be additive to a data set aimed at generating interest from pharmaceutical partners seeking to enter into commercial relationships encompassing Lexaria’s proprietary DehydraTECH technology.